Navigation Links
Fighting cancer with lasers and nanoballoons that pop
Date:4/3/2014

BUFFALO, N.Y. Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.

They often interact with blood, bone marrow and other healthy bodily systems. This dilutes the drugs and causes unwanted side effects.

Now, researchers are developing a better delivery method by encapsulating the drugs in nanoballoons which are tiny modified liposomes that, upon being struck by a red laser, pop open and deliver concentrated doses of medicine.

Described April 3 in the journal Nature Communications, the innovation could improve cancer treatment, reduce its side effects and boost research about the disease, which annually kills millions of people worldwide.

"Why PoP-liposomes, or nanoballoons, open in response to an otherwise harmless red laser is still a bit of a mystery to us, but we have definitely unearthed a new and unique phenomenon," said corresponding author Jonathan Lovell, PhD, UB assistant professor of biomedical engineering. "Its potential for improving how we treat cancer is immense."

Additional authors include students and a research technician at UB, as well as collaborators from the University at Albany; Roswell Park Cancer Institute in Buffalo; and the University of Waterloo and McMaster University, both in Ontario, Canada.

Roughly 1,000 times thinner than human hair, nanoballoons consist of porphyrin, an organic compound, and phospholipid, a fat similar to vegetable oil. Like conventional chemotherapy, they would be delivered to patients intravenously.

But because the nanoballoons encapsulate the anti-cancer drugs, they diminish the drugs' interaction with healthy bodily systems.

In laboratory experiments performed with mice, Lovell hits the nanoballoon with a red laser at the target site in the body. The laser triggers the nanoballoons to pop open and release the drugs. As soon as the laser is turned off, the nanoballoons close, taking in proteins and molecules that might induce cancer growth. Doctors could then be able to retrieve the nanoballoons by drawing blood or taking a biopsy.

Thus, the nanotechnology could provide a "chemical snapshot" of the tumor's environment, which otherwise is very difficult to assess.

"Think of it this way," Lovell said. "The nanoballoon is a submarine. The drug is the cargo. We use a laser to open the submarine door which releases the drug. We close the door by turning the laser off. We then retrieve the submarine as it circulates through the bloodstream."

Lovell will continue fundamental studies to better understand why the treatment works so well in destroying tumors in mice, and to optimize the process. Human trials could start within five years, he said.


'/>"/>

Contact: Cory Nealon
cmnealon@buffalo.edu
University at Buffalo
Source:Eurekalert

Related biology news :

1. Fighting antibiotic resistance with molecular drill bits
2. Success of new bug-fighting approach may vary from field to field
3. Caltech-developed method for delivering HIV-fighting antibodies proven even more promising
4. Fighting flies
5. New strategy emerges for fighting drug-resistant malaria
6. Illinois scientists put cancer-fighting power back into frozen broccoli
7. The duck genome provides new insight into fighting bird flu
8. Germ-fighting vaccine system makes great strides in delivery
9. Biosensor that detects antibiotic resistance brings us one step closer to fighting superbugs
10. Fighting bacteria with a new genre of antibodies
11. Fighting GM crop vandalism with a government-protected research site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
Breaking Biology News(10 mins):
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 ... "Biorefinery Products: Global Markets" report to their offering. ... The ... from $466.6 Billion in 2016 at a CAGR of 8.9%, ... of energetic and non-energetic bioproducts into seven major product segments: ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
Breaking Biology Technology: